Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRX-4 IV-to-oral contezolid versus linezolid IV-to-oral for resistant Gram-positive infections in Chinese adults
CTR20251837Phase 3Active
- Sponsor
- MicuRx Pharmaceuticals
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of contezolid in Gram-positive bacterial infection, acute bacterial skin and skin structure infection (ABSSSI), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), Healthcare-associated pneumonia (HCAP), sponsored by MicuRx Pharmaceuticals. Started Aug 2025; status: active.
02
Drugs
contezolid
03
Conditions
Gram-positive bacterial infectionacute bacterial skin and skin structure infection (ABSSSI)hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Healthcare-associated pneumonia (HCAP)
Beyond the preview
Go deeper on CTR20251837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251837.